Biosimilar Adoption and Provider Performance in Medicare Value-Based Payment ModelsByBasit Chaudhry, MD, PhD,Andrew Yue, PhD,Ahmed Shelbaya, MD,Lisa Tran, BS,Joshua A. Roth, PhD, MHAMay 5th 2026
Initiation of the Interchangeable Biosimilar Insulin Glargine-yfgn Among Older AdultsByShivani R. Khan, PhD,Debra A. Heller, PhD, MPH,Leroy L. Latty, MS,Michelle LaSure, RPh,Theresa V. Brown, MPA April 17th 2026
Aflibercept Biosimilar Showed Improvements in RVO-Associated Macular EdemaByJulia BonavitacolaMarch 11th 2026
Biosimilar Interchangeability and Substitution in the US: What Comes Next?ByBenjamin N. Rome, MD, MPH,Anushka Bhaskar, MPhil,Aaron S. Kesselheim, MD, JD, MPHOctober 30th 2025
